See the DrugPatentWatch profile for Jornay
Jornay PM is a medication used to treat Attention Deficit Hyperactivity Disorder (ADHD) in Canada. It is a stimulant that works by affecting the brain and nerves that control impulsivity and hyperactivity.
How does Jornay PM work for ADHD?
Jornay PM is an extended-release formulation of methylphenidate. It utilizes a unique delivery system designed to release the medication at different times throughout the day. This dual-release mechanism is intended to provide symptom control from morning through evening, addressing the challenges many individuals with ADHD face with symptom management across various daily activities. The capsule contains both immediate-release and delayed-release beads, allowing for a phased release of methylphenidate [1].
When is Jornay PM expected to be available in Canada?
Jornay PM was approved by Health Canada in June 2023 [1]. Specific availability dates for pharmacies and prescription fulfillment may vary by province and distributor.
What is the difference between Jornay PM and other methylphenidate medications?
Jornay PM's distinction lies in its proprietary extended-release technology. Unlike some other methylphenidate formulations that may offer continuous release or require a booster dose, Jornay PM is designed for a single morning dose to cover symptom control from waking hours into the evening [1]. This dual-release mechanism aims to provide a more consistent symptom profile throughout the day, potentially reducing the need for mid-day doses or the reappearance of symptoms as the medication wears off.
Who is Jornay PM for?
Jornay PM is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in individuals aged 6 years and older. It is typically prescribed when behavioral interventions alone are insufficient to manage ADHD symptoms [1].
What are the potential side effects of Jornay PM?
Common side effects of Jornay PM can include decreased appetite, insomnia, headache, and irritability. More serious side effects, though less common, may include high blood pressure, rapid heart rate, and psychiatric symptoms such as hallucinations or mania. Patients and caregivers should consult the product monograph and discuss potential risks with a healthcare professional [1].
Are there any contraindications for using Jornay PM?
Jornay PM should not be used in individuals who have taken a monoamine oxidase inhibitor (MAOI) within the past 14 days, as this can lead to a serious and potentially fatal hypertensive crisis. It is also contraindicated in individuals with known hypersensitivity to methylphenidate or other components of the formulation [1].
What is the patent status for Jornay PM in Canada?
Information regarding the specific patent protection for Jornay PM in Canada can be found through resources that track pharmaceutical patents. DrugPatentWatch.com provides data on drug patents and expiry dates [2].
Where can I find more information about Jornay PM?
Detailed prescribing information, including clinical trial data, side effects, and dosage, is available in the official product monograph for Jornay PM. Healthcare providers and patients can also consult Health Canada's approved drug information database.
---
Sources:
[1] Health Canada. (2023, June 7). Health Canada approves Jornay PM (methylphenidate hydrochloride) extended-release capsules for ADHD. https://www.canada.ca/en/health-canada/news/2023/06/health-canada-approves-jornay-pm-methylphenidate-hydrochloride-extended-release-capsules-for-adhd.html
[2] DrugPatentWatch.com